Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Nosopharm
Nosopharm
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
Bayer HealthCare and Johns Hopkins University to collaborate on new ophthalmic therapies
The partners will work jointly on the discovery and development of innovative drugs for the treatment of serious back-of-the-eye diseases
Berry Global invests to increase production capacity for healthcare products
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
French collaboration aims to address antibiotic resistance
The project will involve the creation of chemical libraries of bioactive molecules for Nosopharm’s anti-infective screening campaigns against antibiotic resistance
Recruitment
Nosopharm bolsters supervisory board
Research & Development
Nosopharm joins European Gram-negative Antibacterial Engine (ENABLE) project to combat antibiotic resistance
The company aims to advance a promising antibacterial compound to clinical stage for the treatment of multidrug-resistant Gram-negative infections
Research & Development
Nosopharm secures funding of €870,000 to fight antibiotic resistance
Nosopharm has developed a new class of antibiotics and the funding will ensure their progression to preclinical development
Subscribe now